Juno Therapeutics, Inc. (NASDAQ:JUNO) reached 32.93% versus a 1-year low price of $17.52. The stock was last seen 3.42% higher, reaching at $23.29 on Jun. 16, 2017. At recent session, the prices were hovering between $22.19 and $23.35. This company shares are 26.66% off its target price of $29.5 and the current market capitalization stands at $2.39B. The recent change has given its price a -3.3% deficit over SMA 50 and -47.57% deficit over its 52-week high. The stock witnessed -5.02% declines, 1.48% gains and 30.26% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found JUNO’s volatility during a week at 4.6% and during a month it has been found around 6.08%.

Juno Therapeutics, Inc. (JUNO) Top Holders

Institutional investors currently hold around $1.61 billion or 78.7% in JUNO stock. Look at its top three institutional owners. Crestline Management, Lp owns $404.05 million in Juno Therapeutics, Inc., which represents roughly 16.91% of the company’s market cap and approximately 25.03% of the institutional ownership. Similar statistics are true for the second largest owner, Baillie Gifford & Co, which owns 11,197,863 shares of the stock are valued at $260.8 million. The third largest holder is Vanguard Group Inc, which currently holds $143.32 million worth of this stock and that ownership represents nearly 6% of its market capitalization.

Juno Therapeutics, Inc. 13F Filings

At the end of Mar reporting period, 81 institutional holders increased their position in Juno Therapeutics, Inc. (NASDAQ:JUNO) by some 6,033,027 shares, 77 decreased positions by 4,128,319 and 27 held positions by 59,157,022. That puts total institutional holdings at 69,318,368 shares, according to SEC filings. The stock grabbed 29 new institutional investments totaling 2,134,183 shares while 27 institutional investors sold out their entire positions totaling 2,651,692 shares.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Insider Trades

Multiple company employees have indulged in significant insider trading. Juno Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Klausner Richard has sold 24,000 shares of Juno Therapeutics, Inc. (JUNO) in trading session dated Jun. 07, 2017. These shares are worth $566,400 and were traded at $23.6 each. The SEC filing shows that FLATLEY JAY T performed a purchase of 20,000 shares. The Director added these shares by way of transaction on May. 26, 2017. The company’s shares were assimilated at $24.76 per share worth to an investment of some $495,200 on account of FLATLEY JAY T.

Director, EVNIN ANTHONY B, purchased 8,000 common shares of Juno Therapeutics, Inc. (JUNO) in the open market. In a transaction dated Mar. 10, 2017, the shares were bought at an average price of $22.11, giving away a sum of $176,880. After this purchase, 56,990 common shares of JUNO are directly owned by the insider, with total stake valued at $1,327,297.

In the transaction dated Nov. 10, 2016, the great number of shares disposed came courtesy the EVP & Chief Commercial Officer; Azelby Robert disposed a total of 12,921 shares at an average price of $24.14, amounting to approximately $311,913. The insider now directly owns 35,719 shares worth $831,896.

Juno Therapeutics, Inc. (JUNO) Analyst Guide

Several analysts have released their opinion on Juno Therapeutics, Inc. (NASDAQ:JUNO), with 3 analysts believing it is a strong buy. Whereas 7 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 1 strong sell ratings, collectively assigning a 2.64 average brokerage recommendation.